111In[In]-DTPA-EGF was administered to patients with EGFR-positive BC in amounts up to 2,290 MBq in a Phase 1 clinical trial of MAE peptide radiotherapy (Vallis et al. 2014). Here, EGFR is linked to breast cancer.